BI Asset Management Fondsmaeglerselskab A S Reduces Position in Medpace Holdings, Inc. $MEDP

Key Points

• BI Asset Management Fondsmaeglerselskab A S reduced its stake in Medpace Holdings, Inc. by 50.5% in the first quarter, now holding 7,868 shares valued at approximately $2.4 million.
• Analysts have set varying price targets for Medpace, with Deutsche Bank raising its target from $270.00 to $430.00 while a report by TD Cowen reaffirmed a sell rating with a revised target of $366.00.
• Medpace's stock recently experienced a 2.7% decline, opening at $453.34 per share after a strong quarterly earnings report detailing revenue of $603.31 million and a net margin of 18.74%.

BI Asset Management Fondsmaeglerselskab A S cut its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 50.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,868 shares of the company's stock after selling 8,025 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Medpace were worth $2,397,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Whittier Trust Co. increased its stake in shares of Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares in the last quarter. Benjamin Edwards Inc. increased its stake in shares of Medpace by 3.1% in the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock worth $366,000 after purchasing an additional 36 shares in the last quarter. Assetmark Inc. increased its stake in shares of Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after purchasing an additional 43 shares in the last quarter. Proficio Capital Partners LLC increased its stake in shares of Medpace by 6.4% in the first quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after purchasing an additional 47 shares in the last quarter. Finally, Park Avenue Securities LLC increased its stake in shares of Medpace by 1.8% in the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock worth $838,000 after purchasing an additional 48 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Medpace

In other news, CEO August J. Troendle sold 48,487 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $451.69, for a total value of $21,901,093.03. Following the sale, the chief executive officer directly owned 962,615 shares in the company, valued at $434,803,569.35. The trade was a 4.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $450.14, for a total transaction of $3,376,050.00. Following the completion of the sale, the vice president owned 57,500 shares in the company, valued at approximately $25,883,050. This trade represents a 11.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 114,450 shares of company stock worth $51,791,251. 20.30% of the stock is currently owned by corporate insiders.

Medpace Price Performance

Shares of Medpace stock traded up $10.30 during trading hours on Friday, reaching $463.64. The company's stock had a trading volume of 328,935 shares, compared to its average volume of 403,145. The firm has a 50 day moving average price of $378.86 and a 200-day moving average price of $334.87. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $501.30. The stock has a market cap of $13.02 billion, a P/E ratio of 34.47, a P/E/G ratio of 2.92 and a beta of 1.42.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. During the same period in the previous year, the firm posted $2.75 EPS. The business's quarterly revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MEDP. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. UBS Group downgraded shares of Medpace from a "neutral" rating to a "sell" rating and lifted their price target for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. William Blair reiterated a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Finally, Barclays lifted their price target on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus target price of $406.60.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.